Keyphrases
Acute Coronary Syndrome
100%
Atrial Fibrillation
100%
Triple Therapy
100%
Non-vitamin K Antagonist Oral Anticoagulants
60%
Bleeding
60%
Aspirin
60%
Dual Antiplatelet Therapy
60%
Bleeding Risk
40%
Risk Stratification
40%
P2Y12 Inhibitors
40%
Clopidogrel
40%
Subacute Phase
40%
Adverse Cardiac Events
40%
Rivaroxaban
40%
Ischemic Events
20%
Dual Therapy
20%
Ticagrelor
20%
Secondary Prevention
20%
Antithrombotic Therapy
20%
Prasugrel
20%
Intracranial Hemorrhage
20%
Oral Anticoagulants
20%
Ischemic Risk
20%
Antithrombotic Agents
20%
Vorapaxar
20%
Cilostazol
20%
Individualized Treatment
20%
Prior Stroke
20%
PAR-1 Antagonist
20%
Medicine and Dentistry
Acute Coronary Syndrome
100%
Atrial Fibrillation
100%
Antithrombotic
100%
Acetylsalicylic Acid
50%
Antiplatelet
50%
Risk Stratification
33%
Major Adverse Cardiac Event
33%
Clopidogrel
33%
Rivaroxaban
33%
Bleeding
33%
Low Drug Dose
16%
Ticagrelor
16%
Secondary Prevention
16%
Prasugrel
16%
Cerebral Hemorrhage
16%
Apoplexy
16%
Proteinase Activated Receptor 1
16%
Vorapaxar
16%
Cilostazol
16%
Transient Ischemic Attack
16%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Anticoagulant Agent
100%
Acute Coronary Syndrome
100%
Antiplatelet
50%
Acetylsalicylic Acid
50%
Vitamin K Group
50%
Rivaroxaban
33%
Clopidogrel
33%
Bleeding
33%
Major Adverse Cardiac Event
33%
Vorapaxar
16%
Prasugrel
16%
Proteinase Activated Receptor 1
16%
Transient Ischemic Attack
16%
Cerebrovascular Accident
16%
Cilostazol
16%
Ticagrelor
16%
Brain Hemorrhage
16%
Neuroscience
Antithrombotic
100%
Acute Coronary Syndrome
100%
Atrial Fibrillation
100%
Aspirin
50%
Vitamin K
50%
Rivaroxaban
33%
P2Y12
33%
Clopidogrel
33%
Cerebrovascular Accident
16%
Prasugrel
16%
Cerebral Hemorrhage
16%
Ticagrelor
16%
Cilostazol
16%
Vorapaxar
16%
Proteinase Activated Receptor 1
16%